PEG Interferon α-2b (PEG-Intron) in Essential Thrombocythemia: Phase II study for determination of the minimum effective, safe and tolerated dose. Preliminary data

MLA

Luigi, Gugliotta, et al. PEG Interferon α-2b (PEG-Intron) in Essential Thrombocythemia: Phase II Study for Determination of the Minimum Effective, Safe and Tolerated Dose. Preliminary Data. Jan. 2001. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......4731..c5059efd12e765538e9c04ea4dddebbf&authtype=sso&custid=ns315887.

APA

Luigi, G., Domenico, R., Nicola, V., Silvia, C., Simona, B., Barbara, G., Anna, C., Vincenzo, M., Roberto, L., Serena, R., Alfonso, Z., Stefano, S., Ercole De Biasi, Francesco, P., Maurizio, M., Sara, G., Antonio, T., Alberto, G., Cacciola, E., … Michele, B. (2001). PEG Interferon α-2b (PEG-Intron) in Essential Thrombocythemia: Phase II study for determination of the minimum effective, safe and tolerated dose. Preliminary data.

Chicago

Luigi, Gugliotta, Russo Domenico, Vianelli Nicola, Caglio Silvia, Bulgarelli Simona, Gamberi Barbara, Candoni Anna, et al. 2001. “PEG Interferon α-2b (PEG-Intron) in Essential Thrombocythemia: Phase II Study for Determination of the Minimum Effective, Safe and Tolerated Dose. Preliminary Data,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......4731..c5059efd12e765538e9c04ea4dddebbf&authtype=sso&custid=ns315887.